Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis
-LEO Pharma A/S, a global leader in medical dermatology, today announced 16-week results of a 52-week monotherapy trial showing tralokinumab significantly improved primary and secondary measurements of efficacy among adolescents (aged 12 to 17) with moderate-to-severe atopic dermatitis.1?The week 16 results from the Phase 3 ECZTRA 6?trial were shared during the 2021 Fall Clinical Dermatology Conference held virtually and with a hybrid option in Las Vegas.
Tralokinumab is a high-affinity, human monoclonal antibody that specifically binds to and inhibits IL-13, a key driver of atopic dermatitis signs and symptoms.2,3?It is an investigational therapy in clinical development in the United States and has not been approved by the U.S. Food and Drug Administration. It has been approved for the treatment of adults with moderate-to-severe atopic dermatitis by the European Commission and the MHRA in June 2021 and by Health Canada in October 2021. ?After 16 weeks, adolescents who received either dose of tralokinumab, without rescue therapy, showed significantly greater improvement in atopic dermatitis signs and symptoms and quality of life compared to those receiving placebo,? said Amy Paller, M.D., Chair, Department of Dermatology, Feinberg School of Medicine, Northwestern University in Chicago, Illinois, and the international coordinating investigator for ECZTRA 6. ?These findings are encouraging, as moderate-to-severe atopic dermatitis can have major physical and psychosocial impacts on adolescents who have limited options for long-term treatment.? The 16-week initial treatment period of the ECZTRA 6 trial (NCT03526861) assessed the efficacy and safety of tralokinumab 150 mg (n=98) or 300 mg (n=97) every two weeks (Q2W) compared to placebo (n=94) in adolescents.1?At week 16, tralokinumab met its primary and secondary endpoints, showing significantly more patients treated with tralokinumab achieved a clinical response, compared to placebo, defined as achieving an IGA 0/1 and/or an EASI-751:?These findings are encouraging, as moderate-to-severe atopic dermatitis can have major physical and psychosocial impacts on adolescents who have limited options for long-term treatment.?
Tweet this
- 21.4% (p<0.001) of the tralokinumab 150 mg group and 17.5% (p=0.002) of the tralokinumab 300 mg group achieved clear or almost-clear skin compared to 4.3% with placebo as measured by IGA.1
- 28.6% (p<0.001) of the tralokinumab 150 mg group and 27.8% (p=0.001) of the tralokinumab 300 mg group achieved 75% or greater disease improvement from baseline compared to 6.4% with placebo as measured by EASI.1
- Paller A. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. Fall Clinical. Oct. 21-24, 2021. Poster Presentation.
- Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis.?Allergy. 2020; 75:54-62.
- Popovic B, et al.?Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ra1 and IL-13Ra2.?J Mol Biol. 2017; 429:208?19.
- ClinicalTrials.gov. Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).?https://clinicaltrials.gov/ct2/show/NCT03526861
- Weidinger S, et al. Atopic dermatitis.?Lancet.?2016; 387:1109-1122.
- Boguniewicz M, et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation.?Immunol Rev.?2011;242(1):233-46.
October 2021 MAT-50736